August 3, 2017
WASHINGTON — Today, the Asian & Pacific Islander American Health Forum (APIAHF) released the below statement following the Senate vote on the Prescription Drug User Fee Act (PDUFA), which reauthorizes user fees collected by the Food & Drug Administration (FDA).
“APIAHF welcomes passage of the Prescription Drug User Fee Act, a bill essential for supporting the FDA’s mission,” said Kathy Ko Chin, APIAHF president and CEO. “This bipartisan bill provides funding for the FDA to continue timely review of new medicines that will be used by patients across the country.”
Pharmaceutical drugs and new medicines are critical for millions of Americans, especially those in communities who are disproportionally impacted by chronic conditions. Over half of the chronic Hepatitis B cases in the U.S. are among Asian American and Pacific Islander communities. Cancer is the number one killer for Asian American women. The incidence rates of diabetes in Pacific Islanders are higher than rates among whites. These distinct health challenges facing Asian American, Native Hawaiian and Pacific Islander communities demonstrate the need for continued innovation.